article thumbnail

EU relaxes safety monitoring of CAR-T therapies

Drug Discovery World

The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel).

Therapies 130
article thumbnail

World’s first engineered B cell therapy enters human trials

Drug Discovery World

The first patient has been dosed with an engineered B cell investigational therapy in a Phase I trial in Mucopolysaccharidosis type I (MPS I). Developer Immusoft has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for the therapy, designated ISP-001, in this indication.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

CAR-T therapy could “alter the treatment paradigm” of multiple sclerosis

Drug Discovery World

CAR T-cell therapy involves modifying a patient’s T cells to recognise and remove B cells in the patient’s body. “This very important study will answer whether CAR T-cell therapy offers a new treatment option for patients living with MS. .

Therapies 313
article thumbnail

The killer instinct: Using investigational natural killer therapy to treat Alzheimer’s

Drug Discovery World

DDW Editor Reece Armstrong speaks to Dr Paul Song , MD, NKGen and Dr Vince DeOrchis , clinician, to find out more about the investigational natural killer therapy SNK01 and the benefit of using a patient’s own cells to treat Alzheimer’s. PS : Most, if not all, current therapies are focused on MCI. RA: How does SNK01 work?

Therapies 307
article thumbnail

Gene therapy could reduce seizures in childhood epilepsy

Drug Discovery World

University College London (UCL) researchers have developed a new gene therapy to cure focal cortical dysplasia, which a new study shows can significantly reduce seizures in mice. The post Gene therapy could reduce seizures in childhood epilepsy appeared first on Drug Discovery World (DDW).

Therapies 265
article thumbnail

Advanced Therapies Europe: From bench to bedside and boardroom

Drug Discovery World

Advanced Therapies Europe took place from 9-12 September 2023 in Portugal. DDW’s Megan Thomas asked attendees: What is most important to scale from discovery to commercialisation of cell and gene therapies (CGTs)? Joel Eichmann, Co-Founder, Green Elephant Biotech It always comes down to time-to-market and risk minimisation.

Therapies 291
article thumbnail

First UK patients receive experimental mRNA therapy for cancer

Drug Discovery World

The first UK patients have received an mRNA cancer therapy – mRNA-4359 – as part of a Phase I/II clinical trial investigating its potential for treating melanoma, lung cancer and other solid tumour cancers. The study will assess the therapy administered alone or in combination with immune checkpoint inhibitor pembrolizumab.

Therapies 279